The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The Role of RASSF1A Methylation in Cancer
Open accessAbstract
Tumour suppressor gene inactivation is critical to the pathogenesis of cancers; such loss of function may be mediated by irreversible processes such as gene deletion or mutation. Alternatively tumour suppressor genes may be inactivated via epigenetic processes a reversible mechanism that promises to be more amenable to treatment by therapeutic agents. The CpG dinucleotide is under‐represented in the genome, but it is found in clusters within the promoters of some genes, and methylation of these CpG islands play a critical role in the control of gene expression. Inhibitors of the DNA methyltransferases DNMT1 and DNMT3b have been used in a clinical setting, these nucleotide analogues lack specificity but the side effects of low dose treatments were minimal and in 2004 Vidaza (5‐azacitidine) was licensed for use in myelodysplastic syndrome. Methylation inhibitors are also entering trials in conjunction with another class of epigenetic modifiers, the histone deacetylase inhibitors and this epigenetic double bullet offers hope of improved treatment regimes. Recently there has been a plethora of reports demonstrating epigenetic inactivation of genes that play important roles in development of cancer, including Ras‐association domain family of genes. Epigenetic inactivation of RASSF1A (Ras‐association domain family 1, isoform A) is one of the most common molecular changes in cancer. Hypermethylation of the RASSF1A promoter CpG island silences expression of the gene in many cancers including lung, breast, prostate, glioma, neuroblastoma and kidney cancer. Several recent studies have illustrated the diagnostic and prognostic potential of RASSF1A methylation. This presents RASSF1A methylation as an attractive biomarker for early cancer detection which, for most cancers, results in improved clinical outcome. DNA methylation analysis is applicable to a range of body fluids including serum, urine, bronchioalveolar lavage and sputum. The ease with which these body fluids can be acquired negates the need for invasive procedures to obtain biopsy material. This review will discuss the feasibility of using RASSF1A methylation as a diagnostic and prognostic marker in cancer management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methylated DNA collected by tampons: a new tool to detect endometrial cancer.
Fiegl, H., Gattringer, C., Widschwendter, A., Schneitter, A., Ramoni, A., Sarlay, D., Gaugg, I., Goebel, G., Müller, H. M., Mueller-Holzner, E., et al. (2004) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.882.13.5 · Cited by 123
Cited by
Donninger, H., Vos, M. D., & Clark, G. J. (2007) · Journal of Cell Science · doi:10.1242/jcs.010389 · Cited by 440
Cancer epigenetics: linking basic biology to clinical medicine
Tsai, H.-C., & Baylin, S. B. (2011) · Cell Research · doi:10.1038/cr.2011.24 · Cited by 297
Cancer Epigenetics: Modifications, Screening, and Therapy
Einav Nili, G.-Y., Saito, Y., Egger, G., & Jones, P. A. (2008) · Annual Review of Medicine · doi:10.1146/annurev.med.59.061606.095816 · Cited by 270
The effects of mutant Ras proteins on the cell signalome
Takács, T., Kudlik, G., Kurilla, A., Szeder, B., Buday, L., & Vas, V. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09912-8 · Cited by 62
Metadata
- Authors
- Hesson, L. B., Cooper, W. N., & Latif, F.
- Venue
- Disease Markers
- Publisher
- Wiley
- Published
- 2007-01
- Volume
- 23
- Issue
- 1-2
- Pages
- 73-87
- ISSN
- 0278-0240 (ISSN-L)
- 1875-8630
- OpenAlex
- W1966598245
- Cited by
- 218
- References
- 1
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Role of RASSF1A Methylation in Cancer. https://app.cochat.ai/papers/10.1155/2007/291538
- The paper
- Hesson, L. B., Cooper, W. N., & Latif, F. (2007). The Role of RASSF1A Methylation in Cancer. Disease Markers. https://doi.org/10.1155/2007/291538
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.